FIELD: medicine.
SUBSTANCE: invention belongs to medicine and pharmacology, notably to antitumour agent for gastrointestinal tract cancer treatment. Agent includes component (A) and component (B). Component (A) is R-(-)-3-[3-(1-tret-butylcarbonylmethyl-2-oxo-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-bensodiazepine-3-yl)ureido]bensoic acid or its pharmaceutically acceptable salt. Component (B) is antitumour agent.
EFFECT: higher efficiency.
21 cl, 13 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC ANALGESIC | 2009 |
|
RU2486900C2 |
| PREPARATION POTENTIATING RADIATION THERAPY | 2007 |
|
RU2435587C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| REINFORSING AGENT FOR RADIATION THERAPY, WHICH INCLUDES PYRIDINE DERIVATIVE AS ACTIVE INGREDIENT | 2006 |
|
RU2415670C2 |
| PHARMACEUTICAL COMBINATION FOR CANCER TREATMENT | 2018 |
|
RU2801665C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| TYPES OF COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2727474C2 |
| ANTICANCER THERAPEUTIC AGENT | 2012 |
|
RU2580609C2 |
| COMBINATION THERAPY WITH ANTICANCER ALKALOID | 2018 |
|
RU2767664C2 |
| THERAPEUTIC AGENT FOR BILIARY TRACT CANCER TREATMENT | 2016 |
|
RU2728932C2 |
